The proposed joint venture in India will manufacture, trade, and sell medical devices, with equal partner contribution and Morepen’s 30% stake.

• Morepen Laboratories holds an indirect 30% stake via a subsidiary, ensuring balanced participation and strategic growth in the medical devices market.
• The joint venture will be treated as a related party, while promoters maintain no direct interest beyond Morepen Medipath shareholding.
• Morepen is a vertically integrated pharmaceutical firm offering APIs, branded generics, medical devices, and consumer wellness products globally, with a strong presence.